

**Listing of Claims**

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Original) A method for isolating normal hepatocytes, the method comprising the steps of:

- (a) recovering liver tissue from a patient during a hepatectomy; and
- (b) isolating normal hepatocytes from unwanted cells present in the recovered tissue by magnetic separation.

2. (Original) The method of claim 1 wherein the hepatectomy is performed to resect a liver, or a portion thereof, containing a benign or malignant tumour.

3. (Original) The method of claim 2 further comprising the step of removing macroscopic evidence of the tumour-affected tissue from the recovered liver tissue prior to the step of isolating the hepatocytes by magnetic separation.

4. (Previously presented) The method of claim 1 wherein the unwanted cells are tumour cells.

5. (Previously presented) The method of claim 1 wherein the magnetic separation of cells is achieved using superparamagnetic colloids coated with an antibody.

6. (Original) The method of claim 5 wherein the antibody is a monoclonal antibody which specifically recognises an epitope on the surface of the normal hepatocytes.

7. (Original) The method of claim 5 wherein the antibody is a monoclonal antibody which specifically recognises the unwanted cells.

8. (Original) A method of preparing hepatocytes for transplantation, the method comprising the steps of:

- (c) recovering liver tissue from a patient during a hepatectomy; and
- (d) isolating normal hepatocytes from unwanted cells present in the recovered tissue by magnetic separation.

9. (Original) The method of claim 8 wherein the hepatectomy is performed to resect a liver, or a portion thereof, containing a benign or malignant tumour.

10. (Original) The method of claim 9 further comprising the step of removing macroscopic evidence of the tumour-affected tissue from the recovered liver tissue prior to the step of isolating the hepatocytes by magnetic separation.

11. (Previously presented) The method of claim 8 wherein the unwanted cells are tumour cells.

12. (Previously presented) The method of claim 8 wherein the magnetic separation of cells is achieved using superparamagnetic colloids coated with an antibody.

13. (Original) The method of claim 12 wherein the antibody is a monoclonal antibody which specifically recognises an epitope on the surface of the normal hepatocytes.

14. (Original) The method of claim 12 wherein the antibody is a monoclonal antibody which specifically recognises the unwanted cells.

15. (Previously presented) Normal hepatocytes isolated according to the method of claim 1.

16. (Previously presented) Normal hepatocytes prepared according to the method of claim 8.

17-18. (Cancelled)

19. (Withdrawn) A method for treating a liver disorder in a patient, the method comprising administering to the patient normal hepatocytes isolated according to the method of claim 1 in an amount and for a time sufficient to treat the liver disorder.

---

20. (Withdrawn) The method of claim 19 wherein the liver disorder is selected from the group consisting of: Crigler-Najar Syndrome; Gilbert's Syndrome; Dubin Johnson Syndrome; familial hypercholesterolemia; ornithine transcarbamoylase deficiency; hereditary emphysema; haemophilia; viral hepatitis; hepatocellular carcinoma; acute liver failure; and chronic liver failure.

21. (Previously presented) An artificial liver support system comprising normal hepatocytes isolated according to the method of claim 1.

22. (Previously presented) A method for isolating normal hepatocytes from resected liver tissue recovered during a hepatectomy, said method comprising isolating normal hepatocytes from unwanted cells in the resected tissue by magnetic separation.

23. (Previously presented) A method of preparing normal hepatocytes for transplantation, said method comprising isolating normal hepatocytes, by magnetic separation, from unwanted cells in resected liver tissue recovered during a hepatectomy.

24. (Withdrawn) A method for treating a liver disorder in a patient, the method comprising administering to the patient normal hepatocytes prepared according to the method of claim 8 in an amount and for a time sufficient to treat the liver disorder.

25. (Withdrawn) The method of claim 24 wherein the liver disorder is selected from the group consisting of: Crigler-Najar Syndrome; Gilbert's Syndrome; Dubin Johnson Syndrome; familial hypercholesterolemia; ornithine transcarbamoylase deficiency; hereditary emphysema; haemophilia; viral hepatitis; hepatocellular carcinoma; acute liver failure; and chronic liver failure.